Rosetta Genomics has developed an innovative method to rapidly, robustly, and accurately extract microRNAs from a wide range of sample types. Currently, miRview® tests can be performed on FFPE samples.

Our ability to extract microRNA from FFPE samples is key to the clinical applicability of our cancer diagnostics¹. Because FFPE samples do not require special storage, they may be held at room temperature and sent for evaluation via standard shipping methods.

Once the sample is received by Rosetta Genomics, the microRNA material is extracted and quantitatively evaluated. In the case of miRview® lung eight (8) microRNA biomarkers are used to classify the four main types of lung cancer.

1. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.